Amir Moghadam-Ahmadi, Hossein Khorramdelazad, Gholamhossein Hassanshahi, Sasan Shahsavari, Ali Moadab, Alireza Vakilian
Acta neurologica Belgica 2020 JunParkinson's disease (PD) is one of the most common neuroinflammatory disorders and inflammatory processes seem to play an important role in the pathogenesis of PD. Chemokines as inflammatory mediators, which are involved in the recruitment of leukocytes, can play a role in the pathogenesis of PD. The aim of this study was to examine the serum level of eotaxins (CCL11, CCL24, and CCL26) and the expression of C-C chemokine receptor type 3 (CCR3) in patients with PD compared with healthy subjects. In this study, we measured the serum levels of CCL11, CCL24, and CCL26 with ELISA. In addition, gene and protein expression of CCR3 were measured by RT-PCR and flow cytometry techniques in PD patients (n = 30) and age- and sex-matched healthy subjects (n = 30). All patients suffering from PD were assessed clinically through Unified Parkinson's Disease Rating Scale, Motor Examination (UPDRS ME). The results of this study showed that there was no significant alteration in the serum level of these chemokines and also their receptor among patients with PD and healthy subjects. No significant correlation was observed between the eotaxins serum levels and the clinical measures of PD severity. Based on the results, it can be concluded that eotaxins cannot be considered as appropriate targets for the diagnosis or treatment of PD.
Amir Moghadam-Ahmadi, Hossein Khorramdelazad, Gholamhossein Hassanshahi, Sasan Shahsavari, Ali Moadab, Alireza Vakilian. Eotaxins and C-C chemokine receptor type 3 in Parkinson's disease. Acta neurologica Belgica. 2020 Jun;120(3):589-594
PMID: 30547375
View Full Text